| Ovalbumin Peptide (OVA-II, ISQAVHAAHAEINEAGR)
Functions and Immunological Role: The ovalbumin peptide, OVA-II (ISQAVHAAHAEINEAGR), is a class II MHC-restricted epitope, recognized specifically in mice with the H-2b MHC haplotype. It is critical in immunological studies as a model antigen for studying CD4+ T cell activation and immune responses. This peptide is derived from ovalbumin (OVA), a well-characterized protein, making it a valuable tool in immunological research, particularly for understanding antigen presentation and T-cell responses.
Applications in Scientific Research:
-
Immunotherapy and Vaccine Development: The OVA-II peptide is frequently used in the development of vaccines and immunotherapy studies. Its ability to bind to MHC class II molecules on antigen-presenting cells (APCs) makes it useful for investigating immune responses in cancer immunotherapy and infectious diseases. For instance, artificial proteins incorporating OVA-II can enhance antigen presentation and immune stimulation in experimental setups, improving the efficacy of immunotherapies.
-
T Cell Epitope Mapping: OVA-II is a widely used tool for mapping T cell epitopes. Research shows that it triggers specific CD4+ T cell responses in OT-II transgenic mice, which have the H-2b MHC background. These models help researchers study the specificity of T cell activation and tolerance mechanisms, aiding the understanding of autoimmune diseases, allergies, and vaccine development.
-
Antigen Processing and Presentation Studies: This peptide is instrumental in studying how exogenous proteins are processed by APCs, such as dendritic cells, and presented to helper T cells via MHC class II. Such research provides insights into the cellular mechanisms driving immune responses, both for stimulating immunity (e.g., against tumors or pathogens) and inducing tolerance (e.g., in autoimmune conditions).
Use in Drug Studies: OVA-II peptides are essential in preclinical drug studies where researchers aim to test immunomodulatory drugs or vaccine candidates. By using the OVA model system, drug developers can assess how well a candidate drug enhances or suppresses antigen presentation, aiding in the development of treatments for immune-related diseases like cancer, autoimmune disorders, or chronic infections. The peptide's interaction with immune cells provides a controlled environment for evaluating the efficacy and safety of these treatments before moving to human trials.
Overall, the OVA-II peptide is a cornerstone of immunological research, offering vital insights into the workings of the immune system and providing a platform for testing new therapies and vaccines. Its use in model systems like transgenic mice makes it highly relevant for studying immune regulation and developing new therapeutic approaches.
|
| | 1. Aurora A controls CD8+ T cell cytotoxic activity and antiviral response; Scientific Reports volume 9, Article number: 2211 (2019);
https://www.nature.com/articles/s41598-019-38647-y
...Ovoalbumin peptide (SIINFEKL) was synthesized by LifeTein...
2. Jeon D, Hill E, Moseman JE, McNeel DG. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. J Immunother Cancer. 2024 May 3;12(5):e008799. doi: 10.1136/jitc-2024-008799. PMID: 38702146; PMCID: PMC11086196.
...Ovalbumin peptides for H-2b-restricted class I epitope (SIINFEKL) and class II epitope (ISQAVHAAHAEINEAGR, OVA-II) were synthesized, and the purity and identity were confirmed by mass spectrometry and gas chromatography (LifeTein, Hillsborough, New Jersey, USA)....
|
